#United States #San Diego #Aethlon Medical #Hemopurifier #AEMD

Aethlon Medical's Strategic Funding Move: A $4 Million Follow-On Offering

San Diego-based Aethlon Medical, Inc., listed on NASDAQ under the ticker AEMD, has made headlines with its recent pricing announcement for a follow-on offering valued at approximately $4 million. This strategic move is aimed at bolstering the company's efforts in developing crucial cancer therapies and treatments for life-threatening infectious diseases.

Details of the Offering

The follow-on offering consists of 5,633,009 shares of Aethlon's common stock or pre-funded warrants, along with corresponding warrants that grant the opportunity to purchase an equal number of common shares. The shares and warrants are being offered at a public pricing of $0.7101 each, adhering to NASDAQ’s regulations.

This well-timed offering serves a dual purpose: it provides the necessary capital and allows the company to attract new investors while enhancing liquidity. The company plans to utilize these funds primarily for general corporate purposes, including important areas such as research and development expenses, clinical trial costs, capital expenditures, and overall working capital. Additionally, a portion of the proceeds may be allocated toward acquiring or investing in complementary businesses and technologies, aligning with Aethlon's strategic growth initiatives.

The offering's conclusion is anticipated around July 7, 2026, contingent upon the fulfillment of customary closing conditions. Maxim Group LLC has been appointed as the sole placement agent, showcasing their role in facilitating this significant financial transaction.

The Hemopurifier: Innovation at Aethlon Medical

At the core of Aethlon Medical's mission is its flagship product, the Hemopurifier®. This innovative immunotherapeutic device is designed for treating advanced cancers and severe viral infections. The Hemopurifier has shown promising results in human studies by effectively removing harmful viruses, and it utilizes proprietary lectin-based technology aimed at eradicating unwanted extracellular vesicles (EVs) that are known to promote disease progression and suppress the immune system.

Moreover, the Hemopurifier holds a U.S. Food and Drug Administration (FDA) designation as a Breakthrough Device, particularly beneficial for individuals with cancers resistant to conventional therapies. The device is also under investigation for its efficacy against viral infections that currently lack approved treatment options. This FDA recognition highlights the potential of Aethlon's technology to fundamentally alter patient care in oncology and infectious disease management.

Looking Ahead: Aethlon’s Future in Medical Innovation

The forward-looking statements issued by Aethlon Medical express a cautious optimism regarding closing the offering and achieving projected financial targets. Investors and stakeholders alike are advised to consider the inherent risks surrounding market conditions and the Company's ability to effectively utilize the net proceeds from this offering.

To highlight, the securities pertaining to this offering were registered under a Form S-1 with the Securities and Exchange Commission (SEC), ensuring that all regulatory compliance is met. A preliminary prospectus has already been submitted to the SEC in furtherance of this offering.

In conclusion, Aethlon Medical's well-calibrated follow-on offering could pave the way for significant advancements in cancer care and treatment methodologies, showcasing their commitment to fighting life-threatening diseases through innovative solutions. Industry watchers are keen to see how this financial boost will impact Aethlon’s developmental timeline and market position in the coming years.

For further insights, interested parties can examine the details provided in the prospectus filed with the SEC or contact Aethlon Medical directly.

• ---

For more information about Aethlon Medical's innovative therapies and the Hemopurifier, visit Aethlon Medical.